Miltefosine: issues to be addressed in the future

被引：33

作者：

Berman, J.

Bryceson, A. D. M.

Croft, S.

Engel, J.

Gutteridge, W.

Karbwang, J.

Sindermann, H.

Soto, J.

Sundar, S.

Urbina, J. A.

机构：

[1] London Sch Hyg & Trop Med, London WC1E 7HT, England

[2] DNDi, CH-1201 Geneva, Switzerland

[3] Zentaris GmbH, D-60314 Frankfurt, Germany

[4] WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland

[5] Consorcio Invest Bioclin, Bogota, Colombia

[6] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India

[7] Inst Venezolano Invest Cient, Ctr Biofis & Bioquim, Lab Quim Biol, Caracas 1020A, Venezuela

来源：

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE | 2006年 / 100卷

关键词：

visceral leishmaniasis; cutaneous leishmaniasis; mucosal leishmaniasis; miltefosine; resistance; toxicity;

D O I：

10.1016/j.trstmh.2006.02.009

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice conditions, generation of drug resistance and the need to provide a second antileishmanial agent to protect against this disastrous event, and the ability to maintain reproductive contraceptive practices under routine clinical conditions. (c) 2006 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.

引用

页码：S41 / S44

页数：4

共 20 条

[11] Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania:: A search for reversal agents [J].